

178 Nonbenzodiazepine Sedatives



REFERENCES

- Graham SR, Day RO, Lee R, Fulde GW: Overdose with chloral hydrate: a pharmacological and therapeutic review. *Med J Aust* 149: 686, 1988.
- Bronstein AC, Spyker DA, Cantilena LR Jr, et al: American Association of Poison Control Centers: 2008 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th annual report. *Clin Toxicol (Phila)* 47: 911, 2009.
- Apter JT, Allen LA: Buspirone: future directions. *J Clin Psychopharmacol* 19: 86, 1999.
- Tunnick G: Molecular basis of buspirone's anxiolytic action. *Pharmacol Toxicol* 69: 149, 1991.
- Pecknold JC: A risk-benefit assessment of buspirone in the treatment of anxiety disorders. *Drug Saf* 16: 118, 1997.
- Tiller JW, Burrows GD, O'Sullivan BT: Buspirone overdose. *Med J Aust* 150: 54, 1989.
- Catalano G, Catalano MC, Hanley PF: Seizures associated with buspirone overdose: case report and literature review. *Clin Neuropharmacol* 21: 347, 1998.
- Boyer EW, Shannon M: The serotonin syndrome. *N Engl J Med* 352: 1112, 2005. Erratum in: *N Engl J Med* 356: 2437, 2007.
- Toth PP, Urtis J: Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. *Clin Ther* 26: 1355, 2004.
- Gonzalez LA, Gatch MB, Taylor CM, et al: Carisoprodol-mediated modulation of GABA_A receptors: in vitro and in vivo studies. *J Pharmacol Exp Ther* 329: 827, 2009.
- Littrell RA, Hayes LR, Stillner V: Carisoprodol (Soma): a new and cautious perspective on an old agent. *S Med J* 86: 753, 1993.
- Bramness JG, Mørland J, Sorlid HK, et al: Carisoprodol intoxications and serotonergic features. *Clin Toxicol (Phila)* 43: 39, 2005.
- Bailey DN, Briggs JR: Carisoprodol: an unrecognized drug of abuse. *Am J Clin Pathol* 117: 396, 2002.
- Reeves RR, Beddingfield JJ, Mack JE: Carisoprodol withdrawal syndrome. *Pharmacotherapy* 24: 1804, 2004.
- Pershad J, Palmisano P, Nichols M: Chloral hydrate: the good and the bad. *Pediatric Emerg Care* 15: 432, 1999.
- Greenberg SB, Faerber EN, Aspinall CL, Adams RC: High-dose chloral hydrate sedation for children undergoing MR imaging: safety and efficacy in relation to age. *AJR Am J Roentgenol* 161: 639, 1993.
- Vade A, Sukhani R, Dolenga M, Habisohn-Schuck C: Chloral hydrate sedation of children undergoing CT and MR imaging: safety as judged by American Academy of Pediatrics guidelines. *AJR Am J Roentgenol* 165: 905, 1995.
- Graham SR, Day RO, Lee R, Fulde GW: Overdose with chloral hydrate: a pharmacological and therapeutic review. *Med J Aust* 149: 686, 1988.
- Sing K, Erickson T, Amitai Y, Hryhorczuk D: Chloral hydrate toxicity from oral and intravenous administration. *J Toxicol Clin Toxicol* 34: 101, 1996.
- Zahedi A, Grant MH, Wong DT: Successful treatment of chloral hydrate cardiac toxicity with propranolol. *Am J Emerg Med* 17: 490, 1999.
- Gonzalez A, Nutt DJ: Gamma hydroxyl butyrate abuse and dependency. *J Psychopharmacol* 19: 195, 2005.
- Varela M, Nogué S, Orós M, Miró O: Gamma hydroxybutyrate use for sexual assault. *Emerg Med J* 21: 255, 2004.
- Carter LP, Koek W, France CP: Behavioral analyses of GHB: receptor mechanisms. *Pharmacol Ther* 121: 100, 2009.
- Thai D, Dyer JE, Jacob P, Haller CA: Clinical pharmacology of 1, 4 butanediol and gamma hydroxybutyrate after oral 1, 4 butanediol administration to healthy volunteers. *Clin Pharmacol Ther* 81: 178, 2007.
- Drasbek KR, Christensen J, Jensen K: Gamma-hydroxybutyrate—a drug of abuse. *Acta Neurol Scand* 114: 145, 2006.
- Haller C, Thai D, Jacob P, Dyer JE: GHB urine concentrations after single-dose administration in humans. *J Anal Toxicol* 30: 360, 2006.
- Wong CG, Gibson KM, Snead O: From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid. *Trends Pharmacol Sci* 25: 29, 2004.
- Li J, Stokes SA, Woekener A: A tale of novel intoxication: seven cases of gamma-hydroxybutyric acid overdose. *Ann Emerg Med* 31: 723, 1998.
- Thai D, Dyer JE, Benowitz NL, Haller CA: Gamma-hydroxybutyrate and ethanol effects and interactions in humans. *J Clin Psychopharm* 26: 549, 2006.
- Li J, Stokes SA, Woekener A: A tale of novel intoxication: a review of the effects of gamma-hydroxybutyric acid with recommendations for management. *Ann Emerg Med* 31: 729, 1998.
- Caldicott DG, Kuhn M: Gamma-hydroxybutyrate overdose and physostigmine: teaching new tricks to an old drug? *Ann Emerg Med* 37: 99, 2001.
- Bania TC, Chu J: Physostigmine does not effect arousal but produces toxicity in an animal model of severe gamma-hydroxybutyrate intoxication. *Acad Emerg Med* 12: 185, 2005.
- Zvosec DL, Smith SW, Litonjua R, Westfall RE: Physostigmine for gamma-hydroxybutyrate coma: inefficacy, adverse events, and review. *Clin Toxicol (Phila)* 45: 261, 2007.
- Britt GC, McCance-Katz EF: A brief overview of the clinical pharmacology of "club drugs." *Subst Use Misuse* 40: 1189, 2005.
- Dyer JE, Roth B, Hyma BA: Gamma-hydroxybutyrate withdrawal syndrome. *Ann Emerg Med* 37: 147, 2001.
- Curry DT, Eisenstein RD, Walsh JK: Pharmacologic management of insomnia: past, present, and future. *Psychiatr Clin North Am* 29: 871, 2006.
- Zhdanova IV, Wurtman RJ, Regan MM, et al: Melatonin treatment for age-related insomnia. *J Clin Endocrinol Metab* 86: 4727, 2001.
- Ramakrishnan K, Scheid DC: Treatment options for insomnia. *Am Fam Physician* 76: 517, 2007.
- Holliman BJ, Chyka PA: Problems in assessment of acute melatonin overdose. *South Med J* 90: 451, 1997.
- McGechan A, Wellington K: Ramelteon. *CNS Drugs* 19: 1057, 2005.
- Preskorn SH, Borges-Gonzalez S, Flockhart D: Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: part II. *J Psychiatr Pract* 12: 312, 2006.
- Simpson D, Curran MP: Ramelteon: a review of its use in insomnia. *Drugs* 68: 1901, 2008.
- Borja NL, Daniel KL: Ramelteon for the treatment of insomnia. *Clin Ther* 28: 1540, 2006.
- Reynoldson JN, Elliott E Sr, Nelson LA: Ramelteon: a novel approach in the treatment of insomnia. *Ann Pharmacother* 42: 1262, 2008.
- Sanger DJ: The pharmacology and mechanisms of action of the new generation, nonbenzodiazepine hypnotic drugs. *CNS Drugs* 18 suppl 1: 9, 2004.
- Israel AG, Kramer JA: Safety of zaleplon in the treatment of insomnia. *Ann Pharmacother* 36: 852, 2002.
- Terzano MG, Rossi M, Palomba V, et al: New drugs for insomnia: comparative tolerability of zopiclone, zolpidem, and zaleplon. *Drug Saf* 26: 261, 2003.
- Holm KJ, Goa KL: Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. *Drugs* 59: 865, 2000.
- Garnier R, Guerault E, Muzard D, et al: Acute zolpidem poisoning: analysis of 344 cases. *J Toxicol Clin Toxicol* 32: 391, 1994.
- George CF: Pyrazolopyrimidines. *Lancet* 357: 1623, 2001.
- Dooley M, Plosker GL: Zaleplon: a review of its use in the treatment of insomnia. *Drugs* 60: 413, 2000.
- Weitzel KW, Wickman JM, Augustin SG, Strom JG: Zaleplon: a pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia. *Clin Ther* 22: 1254, 2000.
- Melton ST, Wood JM, Kirkwood CK: Eszopiclone for insomnia. *Ann Pharmacother* 39: 1659, 2005.
- Yell RP: Ethchlorvynol overdose. *Am J Emerg Med* 8: 246, 1990.
- Parry CD, Plüddemann A, Donson H, et al: Cannabis and other drug use among trauma patients in three South African cities, 1999–2001. *S Afr Med J* 95: 429, 2005.
- Faught E: Methaqualone withdrawal syndrome with photoparoxysmal responses and high-amplitude visual evoked potentials. *Neurology* 36: 1127, 1986.

USEFUL WEB RESOURCES

The American Association of Poison Control Centers (AAPCC)—<http://www.aapcc.org/DNN>
 The American Academy of Clinical Toxicology (AACT)—<http://www.clintox.org/index.cfm>
 The European Association of Poisons Centres and Clinical Toxicologists (EAPCCT)—<http://www.eapcct.org>
 The Asia Pacific Association of Medical Toxicology (APAMT)—<http://www.asiattox.org>
 The South Asian Clinical Toxicology Research Collaboration (SACTRC)—<http://www.sactrc.org>
 TOXBASE: The primary clinical toxicology database of the National Poisons Information Service—<http://www.toxbase.org>. (Free access for UK National Health Service hospital departments and general practices, NHS Departments of Public Health and Health Protection Agency Units. Available to hospital emergency departments in Ireland by contract. Available to European Poison Centers whose staff are members of the European Association of Poisons Centres and Clinical Toxicologists. Overseas users may be allowed access on payment of a yearly subscription, subject to approval of the Health Protection Agency.)